SAN

99.11

-3.51%↓

EI

265.5

-0.82%↓

SHL.DE

49.33

-1.62%↓

ARGX

524.6

-3.81%↓

FRE

38.83

-1.89%↓

SAN

99.11

-3.51%↓

EI

265.5

-0.82%↓

SHL.DE

49.33

-1.62%↓

ARGX

524.6

-3.81%↓

FRE

38.83

-1.89%↓

SAN

99.11

-3.51%↓

EI

265.5

-0.82%↓

SHL.DE

49.33

-1.62%↓

ARGX

524.6

-3.81%↓

FRE

38.83

-1.89%↓

SAN

99.11

-3.51%↓

EI

265.5

-0.82%↓

SHL.DE

49.33

-1.62%↓

ARGX

524.6

-3.81%↓

FRE

38.83

-1.89%↓

SAN

99.11

-3.51%↓

EI

265.5

-0.82%↓

SHL.DE

49.33

-1.62%↓

ARGX

524.6

-3.81%↓

FRE

38.83

-1.89%↓

Search

Genfit

Avatud

SektorTervishoid

3.22 -4.31

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.18

Max

3.37

Põhinäitajad

By Trading Economics

Sissetulek

30M

Müük

61M

P/E

Sektori keskmine

9

73.239

Kasumimarginaal

49.607

Töötajad

169

EBITDA

32M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+163.58% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

24. apr 2025

Turustatistika

By TradingEconomics

Turukapital

166M

Eelmine avamishind

7.53

Eelmine sulgemishind

3.22

Uudiste sentiment

By Acuity

67%

33%

327 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Genfit Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. apr 2025, 23:15 UTC

Suurimad hinnamuutused turgudel

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

1. apr 2025, 23:46 UTC

Market Talk

Market Grapples With Valuing Goodman's Data Centers -- Market Talk

1. apr 2025, 23:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. apr 2025, 23:44 UTC

Market Talk

Global Equities Roundup: Market Talk

1. apr 2025, 23:44 UTC

Market Talk

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

1. apr 2025, 23:43 UTC

Market Talk

Gold Steady, Underpinned by Signs of Chinese Buying Activity -- Market Talk

1. apr 2025, 23:11 UTC

Peamised uudised

Risk Off Trade Is Getting Crowded. It's More Worry Than Panic. -- Barrons.com

1. apr 2025, 23:02 UTC

Market Talk

New Zealand May Be Measuring Stick for Trade-War Fallout -- Market Talk

1. apr 2025, 22:31 UTC

Peamised uudised

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

1. apr 2025, 22:26 UTC

Market Talk

RBA's Focus on What It Doesn't Know Boosts May Cut Odds -- Market Talk

1. apr 2025, 21:47 UTC

Peamised uudised

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

1. apr 2025, 21:32 UTC

Peamised uudised

Hooters' Bankruptcy Is the Latest Sign of Trouble for Restaurants -- Barrons.com

1. apr 2025, 21:06 UTC

Market Talk

Mexican Remittances See Slow Start to the Year -- Market Talk

1. apr 2025, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

1. apr 2025, 20:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

1. apr 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. apr 2025, 20:47 UTC

Peamised uudised

Boeing Stock Drops. Why Lower 737 MAX Production Report Wasn't Quite Right. -- Barrons.com

1. apr 2025, 20:47 UTC

Peamised uudised

BYD Will Beat Tesla Two Ways This Quarter -- Barrons.com

1. apr 2025, 20:20 UTC

Peamised uudised

Trump's 'Liberation Day' Tariffs Loom; Treasury Yields Fall -- WSJ

1. apr 2025, 20:15 UTC

Omandamised, ülevõtmised, äriostud

Eaton Completes Acquisition Of Fibrebond >ETN

1. apr 2025, 20:11 UTC

Market Talk

Altria Stock Seen Overvalued Amid Steep Volume Losses -- Market Talk

1. apr 2025, 20:07 UTC

Omandamised, ülevõtmised, äriostud

Johnson & Johnson Intends to Complete Its Acquisition of Intra-Cellular Therapies on or Around April 2 >JNJ

1. apr 2025, 20:00 UTC

Peamised uudised

Americans Are Worried About Tariffs. Consumer Stocks Could Take a Hit. -- Barrons.com

1. apr 2025, 19:46 UTC

Peamised uudised

Visa, American Express Bidding to Win Apple Credit-Card Network, Sources Say -- WSJ

1. apr 2025, 19:43 UTC

Market Talk

Oil Rally Loses Momentum Ahead of U.S. Tariff Plans -- Market Talk

1. apr 2025, 19:17 UTC

Peamised uudised

Meta's Head of AI Research to Resign Amid Computing Push -- Update

1. apr 2025, 19:13 UTC

Market Talk

U.S. Natural Gas Futures Give Back Gains -- Market Talk

1. apr 2025, 19:03 UTC

Market Talk

Don't Rush Into Trade Talks With U.S., Canadian Experts Advise Lawmakers -- Market Talk

1. apr 2025, 19:00 UTC

Market Talk

Gold Slips Ahead of Tariff Day -- Market Talk

1. apr 2025, 18:54 UTC

Market Talk

Mexican Manufacturing PMIs Reflect Tariff Threats -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Genfit Prognoos

Hinnasiht

By TipRanks

163.58% tõus

12 kuu keskmine prognoos

Keskmine 8.698 EUR  163.58%

Kõrge 9 EUR

Madal 8.4 EUR

Põhineb 2 Wall Streeti analüütiku instrumendi Genfit 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

2

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.28 / 3.315Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Strong Bearish Evidence

Sentiment

By Acuity

327 / 386 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.